Description
CIPVILDIN-M 50/500 Tablet is a combination oral medication produced by Cipla Ltd for the management of Type 2 Diabetes Mellitus. Each tablet contains Vildagliptin 50mg, a DPP-4 inhibitor, and Metformin Hydrochloride IP 500mg, a well-established biguanide anti-diabetic agent.
Vildagliptin helps regulate blood sugar by increasing the levels and activity of incretin hormones, which stimulate glucose-dependent insulin release from the pancreas and suppress the hormone glucagon, thereby preventing excessive glucose production in the liver. Metformin complements these effects by reducing hepatic glucose production, enhancing insulin sensitivity in muscle tissues, and decreasing glucose absorption from the gut. Together, these actions lead to better control of both fasting and postprandial (after meal) blood sugar.
This combination is usually prescribed for adults with Type 2 diabetes when diet, exercise, or monotherapy do not adequately control blood sugar levels. The lower metformin dose (500mg) may be preferred for individuals new to metformin or those sensitive to gastrointestinal side effects.
Typical side effects may include nausea, diarrhea, abdominal discomfort (from metformin), headache, dizziness, mild hypoglycemia (especially with other diabetes medicines or missed meals), and upper respiratory symptoms. Severe kidney impairment, liver dysfunction, and Type 1 diabetes or diabetic ketoacidosis are contraindications for use. Regular kidney and liver
function monitoring, as well as routine blood sugar checks, are recommended during therapy.
CIPVILDIN-M 50/500 Tablets should be taken exactly as directed by your physician, preferably with meals to minimize stomach upset. Adherence to diet, exercise, and regular check-ups is essential for optimal diabetes management with this therapy. Always consult your healthcare provider before making any changes to your diabetes regimen.
Leave a Reply